Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection

阿德福韦 不利影响 医学 耐受性 药代动力学 内科学 胃肠病学 中止 乙型肝炎病毒 乙型肝炎 药理学 拉米夫定 免疫学 病毒
作者
Hong Zhang,Min Wu,Xiaoxue Zhu,Cuiyun Li,Xiaojiao Li,Weili Jin,Dengke Zhang,Hong Chen,Chengjiao Liu,Yanhua Ding,Junqi Niu,Jingrui Liu
出处
期刊:Antiviral Research [Elsevier BV]
卷期号:174: 104693-104693 被引量:16
标识
DOI:10.1016/j.antiviral.2019.104693
摘要

Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities. This study evaluated the tolerability, pharmacokinetics, and antiviral activity of pradefovir in patients with chronic hepatitis B (CHB) virus infection. Non-cirrhotic, treatment-naïve subjects with CHB were divided into five groups (10 patients each) and randomized within each group in a ratio of 6:2:2 to receive an ascending dose of 30, 60, 75, 90, or 120 mg pradefovir, 10 mg adefovir dipivoxil (ADV), or 300 mg tenofovir disoproxil fumarate (TDF) once a day for 28 days. A total of 51 subjects were randomized and 49 subjects completed the study. The groups were well matched and included 39 males, of whom 71% were hepatitis B e-antigen-negative with a mean hepatitis B virus (HBV) DNA level of 6.4–7.16 log10 IU/mL. No subject experienced a serious adverse event or nephrotoxicity. The most frequently reported adverse event was asymptomatic reduction in blood cholinesterase levels in the pradefovir group which recovered without any treatment about 13 ± 7 days after drug discontinuation. This adverse event was not observed in the ADV and TDF groups. The mean changes in serum HBV DNA were −2.78, −2.77, −3.08, −3.18, −3.44, −2.34, and −3.07 log10 IU/mL at 30, 60, 75, 90, and 120 mg pradefovir, 10 mg ADV and 300 mg TDF, respectively, with plateau levels reached with 60 mg pradefovir. Pradefovir and its metabolite PMEA showed linear pharmacokinetics proportional to the dose. The half-life of PMEA in the pradefovir group was 11.47–17.63 h. Short-term use of pradefovir was well tolerated. A decline in HBV DNA levels was superior to TDF at higher doses of pradefovir. 30–60 mg pradefovir is recommended for CHB treatment. CTR20150224.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲的应助被dudu采纳,获得10
刚刚
打打的应助被成就书芹采纳,获得10
刚刚
南一发布了新的文献求助10
刚刚
粒橙酱发布了新的文献求助10
刚刚
hahahaa完成签到,获得积分10
1秒前
1秒前
亭2007完成签到 ,获得积分10
1秒前
1秒前
1秒前
大模型的应助被云雾落清河采纳,获得10
1秒前
2秒前
2秒前
追寻涑完成签到,获得积分10
2秒前
2秒前
液氧发布了新的文献求助10
2秒前
可爱的沅发布了新的文献求助10
2秒前
666关闭了666的文献求助
3秒前
3秒前
3秒前
psj发布了新的文献求助10
3秒前
LL完成签到 ,获得积分10
3秒前
4秒前
hh完成签到,获得积分10
4秒前
LDX发布了新的文献求助10
4秒前
4秒前
5秒前
leesc94完成签到,获得积分10
5秒前
6秒前
李健的小迷弟的应助被绘画采纳,获得10
6秒前
ke发布了新的文献求助10
6秒前
向日葵完成签到,获得积分10
6秒前
紧张的问薇完成签到 ,获得积分10
7秒前
十一发布了新的文献求助10
7秒前
7秒前
yuii完成签到 ,获得积分10
8秒前
melody发布了新的文献求助10
8秒前
西语发布了新的文献求助10
8秒前
FashionBoy的应助被默默采纳,获得30
8秒前
鼻毛好胜发布了新的文献求助10
9秒前
霸气的蜗牛完成签到,获得积分20
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182977
求助须知:如何正确求助?哪些是违规求助? 9572322
关于积分的说明 21824168
捐赠科研通 7779612
什么是DOI,文献DOI怎么找? 3433774
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971